StockNews.com has upgraded Celldex Therapeutics (NASDAQ:CLDX) to “Sell.”
The investment analysts at StockNews.com had previously recommended that shareholders of Celldex Therapeutics (NASDAQ: CLDX) "hold" their shares; however, in ...
Tag: CLDX, Analyst Rating
At StockNews.com, Celldex Therapeutics’ (NASDAQ:CLDX) rating has been raised to “Sell.”
StockNews.com's investing analysts updated their recommendation to "sell" Celldex Therapeutics (NASDAQ:CLDX) in a research note sent to clients and investors ...
Celldex Therapeutics, Inc. (NASDAQ:CLDX) sees a decline of 8.2% in short interest.
In November, short interest in Celldex Therapeutics, Inc. (NASDAQ: CLDX) significantly decreased. 4,130,000 shares were shorted as of November 15th, ...
Celldex Therapeutics (NASDAQ:CLDX) Price Target Reduced to $63.00 by Guggenheim
According to Benzinga, in a letter given to investors on Friday, stock analysts at Guggenheim lowered their price objective for ...
